BG104070A - Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване - Google Patents

Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване

Info

Publication number
BG104070A
BG104070A BG104070A BG10407000A BG104070A BG 104070 A BG104070 A BG 104070A BG 104070 A BG104070 A BG 104070A BG 10407000 A BG10407000 A BG 10407000A BG 104070 A BG104070 A BG 104070A
Authority
BG
Bulgaria
Prior art keywords
interleukin
analogues
ligand
application
chimeric protein
Prior art date
Application number
BG104070A
Other languages
English (en)
Other versions
BG64680B1 (bg
Inventor
Michel Revel
Judith Chebath
Tsvee Lapidot
Orit Kollet
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104070(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of BG104070A publication Critical patent/BG104070A/bg
Publication of BG64680B1 publication Critical patent/BG64680B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретението се отнася до химерни протеини, конструирани чрез сливане на естествено срещани в природата форми на разтворимия IL-6 рецептор, и до IL-6. Те се прилагат за лечение на рак и заболявания на черния дроб, за улесняване на трансплантиранетона костен мозък и за лечение на други състояния, свързани с IL-6.
BG104070A 1997-07-10 2000-01-10 Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване BG64680B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof

Publications (2)

Publication Number Publication Date
BG104070A true BG104070A (bg) 2000-11-30
BG64680B1 BG64680B1 (bg) 2005-11-30

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104070A BG64680B1 (bg) 1997-07-10 2000-01-10 Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване

Country Status (27)

Country Link
US (2) US7198781B1 (bg)
EP (1) EP0991661B1 (bg)
JP (1) JP4402288B2 (bg)
KR (1) KR100505172B1 (bg)
CN (1) CN1185348C (bg)
AR (1) AR013201A1 (bg)
AT (1) ATE342915T1 (bg)
AU (1) AU758161B2 (bg)
BG (1) BG64680B1 (bg)
BR (1) BR9812096B1 (bg)
CA (1) CA2295936C (bg)
CY (1) CY1105895T1 (bg)
CZ (1) CZ302488B6 (bg)
DE (1) DE69836217T2 (bg)
DK (1) DK0991661T3 (bg)
EA (1) EA004793B1 (bg)
EE (1) EE05519B1 (bg)
ES (1) ES2271999T3 (bg)
HK (1) HK1031895A1 (bg)
HU (1) HU225855B1 (bg)
IL (2) IL122818A0 (bg)
NO (1) NO327397B1 (bg)
NZ (1) NZ502139A (bg)
PL (1) PL199212B1 (bg)
PT (1) PT991661E (bg)
SK (1) SK287039B6 (bg)
WO (1) WO1999002552A2 (bg)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
DE69927375T2 (de) * 1998-07-06 2006-06-22 Tosoh Corp., Shinnanyo Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6
HU229148B1 (en) * 1999-03-09 2013-09-30 Zymogenetics Inc Seattle Human cytokine as ligand of the zalpha receptor and uses thereof
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
AU2001274234A1 (en) 2000-06-16 2001-12-24 Asterion Limited Binding agents: chimeric ligand/receptor proteins
US20040057928A1 (en) * 2000-09-14 2004-03-25 Nicole Deglon Use of il-6r/il-6 chimera in huntington's disease
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
AU2003223089A1 (en) * 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd MEDIA FOR BREEDING STEM CELLS
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CA2657934C (en) 2006-07-19 2017-04-04 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
PT2733203T (pt) 2006-08-02 2019-01-23 Technion Res & Dev Foundation Métodos de expansão de células estminais embrionárias numa cultura de suspensão
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2171071B1 (en) * 2007-06-15 2015-08-05 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
US20110182848A1 (en) * 2007-08-03 2011-07-28 Asterion Limited Granulocyte colony stimulating factor
WO2010003101A2 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Il6 immunotherapeutics
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
EP4166652A1 (en) 2009-11-12 2023-04-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SG188411A1 (en) 2010-09-07 2013-04-30 Technion Res & Dev Foundation Novel methods and culture media for culturing pluripotent stem cells
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US20160194369A1 (en) * 2013-08-12 2016-07-07 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of inerest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) * 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) * 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PL197568B1 (pl) * 1997-12-19 2008-04-30 Applied Research Systems Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN

Also Published As

Publication number Publication date
CA2295936C (en) 2009-05-26
PT991661E (pt) 2007-01-31
DE69836217D1 (de) 2006-11-30
EP0991661A2 (en) 2000-04-12
NO327397B1 (no) 2009-06-22
EA200000109A1 (ru) 2000-08-28
JP4402288B2 (ja) 2010-01-20
PL338002A1 (en) 2000-09-25
HK1031895A1 (en) 2001-06-29
AU8127198A (en) 1999-02-08
IL122818A0 (en) 1998-08-16
BR9812096A (pt) 2000-07-18
IL133972A (en) 2015-07-30
WO1999002552A2 (en) 1999-01-21
NZ502139A (en) 2002-03-28
BG64680B1 (bg) 2005-11-30
AU758161B2 (en) 2003-03-20
HU225855B1 (en) 2007-11-28
HUP0002426A2 (hu) 2000-11-28
US7374912B2 (en) 2008-05-20
CN1185348C (zh) 2005-01-19
DE69836217T2 (de) 2007-08-23
CN1269835A (zh) 2000-10-11
CY1105895T1 (el) 2011-02-02
PL199212B1 (pl) 2008-08-29
WO1999002552A3 (en) 1999-04-01
EA004793B1 (ru) 2004-08-26
NO20000086D0 (no) 2000-01-07
NO20000086L (no) 2000-03-08
CZ302488B6 (cs) 2011-06-15
US20070172455A1 (en) 2007-07-26
SK62000A3 (en) 2000-07-11
CA2295936A1 (en) 1999-01-21
JP2001509371A (ja) 2001-07-24
CZ200075A3 (cs) 2000-08-16
ES2271999T3 (es) 2007-04-16
HUP0002426A3 (en) 2003-01-28
ATE342915T1 (de) 2006-11-15
EP0991661B1 (en) 2006-10-18
KR100505172B1 (ko) 2005-08-03
EE05519B1 (et) 2012-02-15
US7198781B1 (en) 2007-04-03
KR20010021522A (ko) 2001-03-15
BR9812096B1 (pt) 2011-09-06
AR013201A1 (es) 2000-12-13
EE200000012A (et) 2000-08-15
SK287039B6 (sk) 2009-10-07
DK0991661T3 (da) 2007-02-05

Similar Documents

Publication Publication Date Title
BG104070A (bg) Химерен протеин на интерлевкин-6 разтворим рецептор/ лиганд, негови аналози и тяхното използване
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE69833779D1 (de) Verfahren und zusammensetzungen zur immunomodulation
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
IL140137A (en) Receptor bodies specifically binding tie-2 ligands
YU17603A (sh) Sintetički proteini koji stimulišu eritropoezu
EP0991618A4 (en) SELECTIVE ANALOGS OF THYROID HORMONES
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
EP1007535A4 (en) METHOD AND PREPARATIONS FOR DIAGNOSTIC AND TREATMENT OF BREAST CANCER
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
IL146125A0 (en) Novel quinones as disease therapies
PT939809E (pt) Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes
HK1025793A1 (en) Hepatitis c receptor protein cd81
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker